Paraneoplastic brain stem encephalitis

Current Treatment Options in Neurology

Volumn 15, Issue 2, 2013, Pages 201-209

  Blaes, Franz ^a  

^a Kreiskrankenhaus Gummersbach   (Germany)

Author keywords

Adrenocorticotropin; Antineuronal; Autoantibodies; Brain stem encephalitis; Corticosteroids; Cyclophosphamide; Differential diagnosis; Immunosuppressive; Immunotherapy; Opsoclonus myoclonus syndrome; Paraneoplastic neurological disease; Rituximab; Treatment; Tumor immunology

Indexed keywords

CORTICOTROPIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; IMMUNOGLOBULIN; METHYLPREDNISOLONE; RITUXIMAB;

ACNE; ALOPECIA; ASEPTIC MENINGITIS; BEHAVIOR DISORDER; BONE DEMINERALIZATION; BONE MARROW SUPPRESSION; BONE NECROSIS; CATARACT; CLINICAL FEATURE; COST EFFECTIVENESS ANALYSIS; CUSHING SYNDROME; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; ELECTROLYTE DISTURBANCE; HEADACHE; HEART ARRHYTHMIA; HEMORRHAGIC CYSTITIS; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFUSION RELATED REACTION; KIDNEY FAILURE; MOUTH DISEASE; NAUSEA; OPSOCLONUS MYOCLONUS SYNDROME; OSTEOPOROSIS; PARANEOPLASTIC BRAIN STEM ENCEPHALITIS; PARANEOPLASTIC NEUROPATHY; PATIENT ASSESSMENT; PLASMAPHERESIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; SEPSIS; SKIN MANIFESTATION; STOMACH PAIN; TREATMENT OUTCOME; TUMOR LYSIS SYNDROME; VOMITING;

EID: 84881231975     PISSN: 10928480     EISSN: 15343138     Source Type: Journal    
DOI: 10.1007/s11940-013-0221-1     Document Type: Review

References (32)

1. Graus F, Dalmau J. Paraneoplastic neurological syndromes. Curr Opin Neurol. 2012;25(6):795-801.
2. Graus F, Delattre JY, Antoine JC, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2004;75(8):1135-40.
3. Saiz A, Bruna J, Stourac P, et al. Anti-Hu-associated brain stem encephalitis. J Neurol Neurosurg Psychiatry. 2009;80(4):404-7.
4. Dalmau J, Graus F, Villarejo A, et al. Clinical analysis of anti-Ma2-associated encephalitis. Brain. 2004;127(Pt8):1831-44.
5. Sutton IJ, Barnett MH, Watson JD, Ell JJ, Dalmau J. Paraneoplastic brain stem encephalitis and anti-Ri antibodies. J Neurol. 2002;249(11):1597-8.
6. Pittock SJ, Parisi JE, McKeon A, et al. Paraneoplastic jaw dystonia and laryngospasm with antineuronal nuclear autoantibody type 2 (anti-Ri). Arch Neurol. 2010;67(9):1109-15.
7. Dalmau J, Tuzun E, Wu HY, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol. 2007;61(1):25-36.
8. Jubelt B, Mihai C, Li TM, Veerapaneni P. Rhombencephalitis/brain stem encephalitis. Curr Neurol Neurosci Rep. 2011;11(6):543-52.
9. Shahrizaila N, Yuki N. Bickerstaff brain stem encephalitis and Fisher syndrome: anti-GQ1b antibody syndrome. J Neurol Neurosurg Psychiatry. 2012; [Epub ahead of print].
10. Simon NG, Parratt JD, Barnett MH, et al. Expanding the clinical, radiological and neuropathological phenotype of chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS). J Neurol Neurosurg Psychiatry. 2012;83(1):15-22.
11. Pranzatelli MR. The immunopharmacology of the opsoclonus-myoclonus syndrome. Clin Neuropharmacol. 1996;19(1):1-47.
12. Luque FA, Furneaux HM, Ferziger R, et al. Anti-Ri: an antibody associated with paraneoplastic opsoclonus and breast cancer. Ann Neurol. 1991;29(3):241-51.
13. Rudnick E, Khakoo Y, Antunes NL, et al. Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: clinical outcome and antineuronal antibodies-a report from the Children's Cancer Group Study. Med Pediatr Oncol. 2001;36(6):612-22.
14. Wong A. An update on opsoclonus. Curr Opin Neurol. 2007;20(1):25-31.
15. Jensen KB, Dredge BK, Stefani G, et al. Nova-1 regulates neuron-specific alternative splicing and is essential for neuronal viability. Neuron. 2000;25(2):359-71.
16. Blaes F, Fuhlhuber V, Korfei M, et al. Surface-binding autoantibodies to cerebellar neurons in opsoclonus syndrome. Ann Neurol. 2005;58(2):313-7.
17. Korfei M, Fuhlhuber V, Schmidt-Woll T, Kaps M, Preissner KT, Blaes F. Functional characterization of autoantibodies from patients with pediatric opsoclonus-myoclonus-syndrome. J Neuroimmunol. 2005;170(1-2):150-7.
18. Fuhlhuber V, Bick S, Kirsten A, et al. Elevated B-cell activating factor BAFF, but not APRIL, correlates with CSF cerebellar autoantibodies in pediatric opsoclonus-myoclonus syndrome. J Neuroimmunol. 2009;210(1-2):87-91.
19. Ule J, Jensen KB, Ruggiu M, Mele A, Ule A, Darnell RB. CLIP identifies Nova-regulated RNA networks in the brain. Science. 2003;302(5648):1212-5.
20. Gambini C, Conte M, Bernini G, et al. Neuroblastic tumors associated with opsoclonus-myoclonus syndrome: histological, immunohistochemical, and molecular features of 15 Italian cases. Virchows Arch. 2003;442(6):555-62.
21. Raffaghello L, Conte M, De Grandis E, Pistoia V. Immunological mechanisms in opsoclonus-myoclonus associated neuroblastoma. Eur J Paediatr Neurol. 2009;13(3):219-23.
22. Graus F, Keime-Guibert F, Rene R, et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain. 2001;124(Pt6):1138-48.
23. Tesseki K, Kataoka H, Terashima M, Kawahara M, Taoka T, Tanaka K, et al. Biphasic paraneoplastic brain stem encephalitis associated with anti-Ri antibody. J Neurooncol. 2010;100(1):141-3.
24. Tay JK, Miller J, Joshi A, Athey RJ. Anti-Ri-associated paraneoplastic cerebellar and brain stem degenerative syndrome. J R Coll Physicians Edinb. 2012;42(3):221-4.
25. Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013. doi: 10.1016/S1474-4422(12) 70310-1.
26. Ertle F, Behnisch W, Al Mulla NA, et al. Treatment of neuroblastoma-related opsoclonus-myoclonus-ataxia syndrome with high-dose dexamethasone pulses. Pediatr Blood Cancer. 2008;50(3):683-7.
27. Pranzatelli MR, Tate ED, Travelstead AL, et al. Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome. J Pediatr Hematol Oncol. 2006;28(9):585-93.
28. Russo C, Cohn SL, Petruzzi MJ, de Alarcon PA. Long-term neurologic outcome in children with opsoclonus-myoclonus associated with neuroblastoma: a report from the Pediatric Oncology Group. Med Pediatr Oncol. 1997;28(4):284-8.
29. Bataller L, Graus F, Saiz A, Vilchez JJ. Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus. Brain. 2001;124(2):437-43.
30. Dropcho EJ, Kline LB, Riser J. Antineuronal (anti-Ri) antibodies in a patient with steroid-responsive opsoclonus-myoclonus. Neurology. 1993;43(1):207-11.
31. Sugie H, Sugie Y, Akimoto H, Endo K, Shirai M, Ito M. High-dose i.v. human immunoglobulin in a case with infantile opsoclonus polymyoclonia syndrome. Acta Paediatr. 1992;81(4):371-2.
32. Wilken B, Baumann M, Bien CG, Hero B, Rostasy K, Hanefeld F. Chronic relapsing opsoclonus-myoclonus syndrome: combination of cyclophosphamide and dexamethasone pulses. Eur J Paediatr Neurol. 2008;12(1):51-5.